BRAF and colorectal carcinoma: These results therefore indicated that in first-line treatment, chemotherapy + bevacizumab for the treatment of patients with advanced CRC with BRAF V600E mutation, has a similar prognosis to chemotherapy alone, and neither may markedly prolong the survival of the patients.